Objectives The goal of this study was to investigate the real therapeutic effectiveness of 6mol % PEG 111In-VNB-liposomes in tumor bearing animal model. Methods Murine colon carcinoma cells transfected with dual reporter genes (CT-26/tk-luc) were xenografted in BALB/c mice. Pharmacokinetics, biodistribution, passive targeting efficiency, and maximum tolerated dose were estimated to determine the biofate and safety dosage of the drugs. Bioluminescence imaging and 18F-FDG microPET were applied for monitoring the therapeutic response after drug administration. The in vivo survival associated with toxicological and histopathological analysis were carried out for defining the safety and feasibility of the nanomedicine. Results 6 mol % PEG 111In-VNB-Liposomes prolonged the circulation time and decreased the radio-accumulation in reticuloendothelial system. The selective tumor uptake was represented by a cumulative deposition post injection. The combination therapy exhibited an additive effect in tumor growth suppression by caliper measuring, BLI and microPET tracing. The better survival and the less tissue toxicity were confirmed with in vivo survival rate, toxicological and histopathological examinations. Conclusions The results demonstrated that the use of acute 6 mol % PEG 111In-VNB-liposomesin the arena of passive targeted tumor therapy might display an addition not onlythrough prolonging the circulation rate and reducing the phagocytic effect on RES, butenhancing the tumor uptake and eventually increasing the survival in tumor-bearing mice.
Date:
2009-05
Relation:
Journal of Nuclear Medicine. 2009 May;50(Suppl. 2):Meeting Abstract 2303.
